4.5 Article

Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee

Journal

JOURNAL OF CARDIAC FAILURE
Volume 21, Issue 6, Pages 519-534

Publisher

CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
DOI: 10.1016/j.cardfail.2015.04.013

Keywords

Heart failure; advanced; stage D

Funding

  1. Thoratec
  2. Biocontrol
  3. Novartis
  4. Shape Systems
  5. St. Jude Medical
  6. Otsuka
  7. National Institutes of Health
  8. National Heart, Lung, and Blood Institute
  9. Patient-Centered Outcome Research Institute
  10. Acorda
  11. Amgen
  12. Cadio3 Bioscienc
  13. Janssen
  14. Mast Therapeutics
  15. Medtronic
  16. St Jude
  17. Trevena
  18. Forest
  19. Merck
  20. ResMed
  21. Pozon
  22. Dalantin
  23. AstraZeneca
  24. Boston Scientific
  25. Bristol-Myers Squibb
  26. GlaxoSmithKline
  27. Portola Pharmaceuticals

Ask authors/readers for more resources

We propose that stage D advanced heart failure be defined as the presence of progressive and/or persistent severe signs and symptoms of heart failure despite optimized medical, surgical, and device therapy. Importantly, the progressive decline should be primarily driven by the heart failure syndrome. Formally defining advanced heart failure and specifying when medical and device therapies have failed is challenging, but signs and symptoms, hemodynamics, exercise testing, biomarkers, and risk prediction models are useful in this process. Identification of patients in stage D is a clinically important task because treatments are inherently limited, morbidity is typically progressive, and survival is often short. Age, frailty, and psychosocial issues affect both outcomes and selection of therapy for stage D patients. Heart transplant and mechanical circulatory support devices are potential treatment options in select patients. In addition to considering indications, contraindications, clinical status, and comorbidities, treatment selection for stage D patients involves incorporating the patient's wishes for survival versus quality of life, and palliative and hospice care should be integrated into care plans. More research is needed to determine optimal strategies for patient selection and medical decision making, with the ultimate goal of improving clinical and patient centered outcomes in patients with stage D heart failure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available